PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.
McDermott MS, Browne BC, Conlon NT, O'Brien NA, Slamon DJ, Henry M, Meleady P, Clynes M, Dowling P, Crown J, O'Donovan N.
McDermott MS, et al. Among authors: clynes m.
Mol Cancer. 2014 Jun 24;13:157. doi: 10.1186/1476-4598-13-157.
Mol Cancer. 2014.
PMID: 24958351
Free PMC article.